<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3663">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473641</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2011_03</org_study_id>
    <nct_id>NCT01473641</nct_id>
  </id_info>
  <brief_title>Nexplanon Observational Risk Assessment Study (NORA)</brief_title>
  <acronym>NORA</acronym>
  <official_title>Nexplanon Observational Risk Assessment Study (NORA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study characterises the frequency of specific insertion-, localization- and&#xD;
      removal-related events and clinically significant consequences thereof among Nexplanon users&#xD;
      in the US during routine clinical use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nexplanon is a subdermal contraceptive implant containing the progestogen etonogestrel. It&#xD;
      provides contraceptive protection for three years. In addition to the progestogen, Nexplanon&#xD;
      contains barium sulfate and a Next Generation Implanon Applicator (NGIA). Nexplanon was&#xD;
      developed to further facilitate correct insertion of the implant by using the NGIA, and to&#xD;
      extend the diagnostic modalities for localization of the implant by making it radiopaque and&#xD;
      visible via X-ray imaging and X-ray Computerized Tomography (CT).&#xD;
&#xD;
      A large, descriptive, prospective, non-interventional, observational cohort study is planned&#xD;
      to follow a cohort of new users of the contraceptive implant Nexplanon. Women will be&#xD;
      recruited through health care professionals who have completed the Nexplanon Clinical&#xD;
      Training Program. Baseline and follow-up information will be collected via a&#xD;
      self-administered questionnaire. Data analysis will include characterizing the frequency of&#xD;
      specific insertion-, localization- and removal-related events via point-estimates of the&#xD;
      event rate as well as 95% confidence intervals. The impact of potential prognostic factors&#xD;
      will be analyzed using multivariate regression models and/or stratified analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insertion-, localization- and removal-related events</measure>
    <time_frame>Within 42 months after insertion</time_frame>
    <description>Incorrect insertion (i.e. unrecognized non-insertion, partial insertion, deep insertion); palpability of the implant at insertion and removal; localization of a non-palpable implant; difficult removals; pregnancy due to unrecognized non-insertion of the implant; injury to neurovascular structures in the arm; hospitalization and/or surgical procedures for localization and/or removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>Within 42 months after insertion</time_frame>
    <description>Pre-treatment, in-treatment, post-treatment and non-insertion pregnancies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Within 42 months after insertion</time_frame>
    <description>Pregnancy outcomes in pregnancies where fetal exposure to etonogestrel may have taken place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for (premature) discontinuation of Nexplanon</measure>
    <time_frame>Within 42 months after insertion</time_frame>
    <description>The reason(s) the patient had the implant removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics of Nexplanon users</measure>
    <time_frame>Within 42 months after insertion</time_frame>
    <description>Baseline characteristics (including contraceptive history, medical history, gynecological history and socio-demongraphic details).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7364</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>New users of Nexplanon</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using the contraceptive implant Nexplanon&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women prescribed a new Nexplanon implant&#xD;
&#xD;
          -  Women who are capable of understanding the major aspects of the study and can complete&#xD;
             the self-administered questionnaire in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are not willing to sign the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaas Heinemann, MD, MBA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Reed S, Do Minh T, Lange JA, Koro C, Fox M, Heinemann K. Real world data on NexplanonÂ® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA). Contraception. 2019 Jul;100(1):31-36. doi: 10.1016/j.contraception.2019.03.052. Epub 2019 Apr 10.</citation>
    <PMID>30980829</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Klaas Heinemann, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Etonogestrel</keyword>
  <keyword>Contraceptive implant</keyword>
  <keyword>Safety</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01473641/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01473641/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

